Glioblastoma and other primary brain malignancies in adults: a review

LR Schaff, IK Mellinghoff - Jama, 2023 - jamanetwork.com
Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …

Harnessing multimodal data integration to advance precision oncology

KM Boehm, P Khosravi, R Vanguri, J Gao… - Nature Reviews …, 2022 - nature.com
Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …

PY Wen, M Weller, EQ Lee, BM Alexander… - Neuro …, 2020 - academic.oup.com
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging

T Hollon, C Jiang, A Chowdury, M Nasir-Moin… - Nature medicine, 2023 - nature.com
Molecular classification has transformed the management of brain tumors by enabling more
accurate prognostication and personalized treatment. However, timely molecular diagnostic …

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

S Venneti, AR Kawakibi, S Ji, SM Waszak, SR Sweha… - Cancer discovery, 2023 - AACR
Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven
effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the …

Mechanisms and therapeutic implications of hypermutation in gliomas

M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu… - Nature, 2020 - nature.com
A high tumour mutational burden (hypermutation) is observed in some gliomas,,,–; however,
the mechanisms by which hypermutation develops and whether it predicts the response to …

Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial

IK Mellinghoff, M Penas-Prado, KB Peters… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy
is associated with short-and long-term toxicity. Progression to higher tumor grade is …

Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

JJ Miller, LN Gonzalez Castro, S McBrayer… - Neuro …, 2023 - academic.oup.com
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …

Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma

IK Mellinghoff, BM Ellingson, M Touat… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Diffuse gliomas are malignant brain tumors that include lower-grade gliomas
(LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is …

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

K Fujimoto, H Arita, K Satomi, K Yamasaki… - Acta …, 2021 - Springer
Abstract The Consortium to Inform Molecular and Practical Approaches to CNS Tumor
Taxonomy (cIMPACT-NOW) update 3 recommends that histologic grade II and III IDH …